GlassScriptPhysician profile
Michael J Sullivan
NPI 1528076197
$1,631.53
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $461 · 2020: $193 · 2021: $531 · 2022: $337 · 2023: $27.23 · 2024: $82.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $67.99 · Food and Beverage: $41.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $67.99 |
| Food and Beverage | $41.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $322.29 | 2019-2021 | |
| Novo Nordisk INC | $297.70 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $140.63 | 2019-2024 | |
| Glaxosmithkline, LLC. | $111.28 | 2019-2022 | |
| Abbvie INC. | $92.24 | 2021-2024 | |
| Amgen INC. | $91.91 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $66.39 | 2021-2022 | |
| Boston Scientific Corporation | $50.90 | 2019-2022 | |
| Genentech USA, INC. | $48.79 | 2019-2021 | |
| Allergan, INC. | $43.92 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.01 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $38.17 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $30.88 | 2022 | |
| Astellas Pharma US INC | $28.87 | 2019-2022 | |
| Octapharma USA, INC. | $27.23 | 2023 | Octagam Immune Globulin (Human) |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $22.34 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.88 | 2022 | |
| Medtronic, INC. | $19.06 | 2022 | |
| Philips North America LLC | $19.03 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.80 | 2021 | |
| Organon LLC | $16.47 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.76 | 2021 | |
| Adma Biomanufacturing LLC | $15.48 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $14.20 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.03 | 2021 | |
| Dexcom, INC. | $12.29 | 2022 | |
| Novartis Pharmaceuticals Corporation | $11.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.